市中感染症に対するclarithromycinの有効性および安全性に関する使用成績調査（第２報）－臨床症状と原因菌からの解析－

Post-marketing surveillance of efficacy and safety of clarithromycin in community-acquired infectious diseases. 2nd report. Analysis of clinical manifestations and pathogenic bacteria.

　市中感染症に対するclarithromycin（CAM：クラリス®）の使用成績調査を行った。得られた成績のうち，承認用量かつ適応疾患症例について，臨床症状および原因菌の観点から解析した。その結果，呼吸器感染症の症状消失率は，咳嗽で67.2％，喀痰で77.5％，咽頭痛で93.8％であった。原因菌別の有効率は，Streptococcus pneumoniaeで100.0％，Haemophilus influenzaeで100.0％であり，Moraxella catarrhalisで100.0％であった。急性副鼻腔炎における症状消失率は，鼻漏・後鼻漏で78.4％，鼻閉で85.5％，急性中耳炎における症状消失率は，耳痛で100.0％，鼓膜発赤で91.7％であった。原因菌別有効率は，S. pneumoniaeで90.5％，H. influenzaeで78.9％であった。皮膚科領域感染症における症状消失率は，発赤・腫脹で76.6％，膿疱で82.6％であった。原因菌別有効率は，Staphylococcus aureusで5例中４例，Staphylococcus epidermidisで４例中４例であった。以上より，症状消失率および原因菌別有効率の観点から，本薬の有用性を支持する結果が得られた。

　A post-marketing surveillance study was implemented regarding use of clarithromycin（CAM, Clarith®）for community-acquired infectious disease. In the results obtained, we analyzed the approval dosage and cases of diseases for which CAM is indicated, from a viewpoint of clinical symptoms and a causative organism.［Result］The eradication rate of clinical symptoms for respiratory tract infectious diseases were 67.2％for cough, 77.5％for sputum, and 93.8％for sore throat, respectively. The clinical efficacy rate by the pathogen type was 100.0％ for Streptococcus pneumoniae, 100.0％ for Haemophilus influenzae, and 100.0％ for Moraxella catarrhalis, respectively. The eradication rate of clinical symptoms for acute sinusitis was 78.4％ for rhinorrhea/postnasal drip and 85.5％ for nasal congestion. The eradication rate of clinical symptoms for acute otitis media was 100.0％ for aural pain and 91.7％ for eardrum redness. The clinical efficacy rate by the pathogen type was 90.5％ for S. pneumoniae and 78.9％ for H. influenzae, respectively. The eradication rate of clinical symptoms for dermatological infections was 76.6％ for redness/swelling and 82.6％ for pustules. The clinical efficacy rate by the pathogen type was 4 cases out of 5 for Staphylococcus aureus and 4 cases out of 4 for Staphylococcus epidermidis, respectively.［Conclusion］From the above, the results supported the usefulness of this drug from the standpoints of both eradication rates of clinical symptoms and the clinical efficacy rate by the pathogen type.